Biotech News - Myogen, Inc. (Public, NASDAQ:MYOG)

Myogen, Inc. (Public, NASDAQ:MYOG)

J. William Freytag, Ph.D., President & CEO of Myogen to Be Special
Guest at 14th Annual Biotech Investing Conference

NEW YORK, NY -- October 26, 2006 -- IBF Conferences, Inc. and SRI
International today announced that J. William Freytag, Ph.D.,
President & CEO of Myogen, will be a special guest at the 14th
Annual Biotech Investing Conference held at SRI International at
Menlo Park, CA.

Mr. Freytag will be the special guest during the fireside chat to be
held on November 8th at 4:30 PM. Camille Samuels, Managing Director
of Versant Ventures, will be conducting the interview and said of
Mr. Freytag, "Bill has been at the helm of Myogen since 1998 -- and
successfully led the company through many of biotech's toughest
challenges including fundraising in difficult times and managing
through a product failure. Now, Bill is preparing to transition
Myogen to its acquirer, Gilead, for $2.5 Billion! Every student of
biotechnology can learn from Bill's experiences and thoughtful
approach."

The 14th Annual Biotech Investing Conference, November 8, 2006,
being held at SRI International, is a program to keep venture
investors informed of emerging trends in the biotech sector, as well
as investing strategies and collaborative business opportunities. In
addition, the conference will also provide big pharma's perspective
on rebuilding the pipeline and a look at how foundations are
becoming a tool to fund early-stage research. There will also be an
NVCA hosted pre conference reception held on November 7th --
CELEBRATE THE EMERGENCE OF A NEW CLASS OF BIOTECH INVESTORS -- which
is free for all to attend.

Join leading firms such as New Enterprise Associates, Versant
Ventures, CMEA Ventures and Amgen Ventures as well as foundations
such as The Michael J. Fox Foundation for Parkinson's Research and
Cystic Fibrosis Foundation Therapeutics, along with the FDA to
discuss the following topics:

-- TRENDS IN EARLY, MID AND LATER STAGE BIOMEDICAL INVESTING
-- PRIVATE EQUITY INVESTOR & HEDGE FUND APPETITE FOR BIO COMPANIES
-- FOUNDATIONS "BRIDGE THE GAP": PARTNERING WITH VCS AND
ENTREPRENEURS
TO FUND EARLY STAGE BIOTECH
-- BIG PHARMA SPEAKS OUT ON THEIR APPROACH TO FILLING THEIR PIPELINE
-- FDA ACCELERATED DRUG DEVELOPMENT PROGRAMS:
- KEY ISSUES IN ADDRESSING ORPHAN MARKETS
- HOW THE FDA IS SUPPORTING ACCELERATED DRUG DEVELOPMENT
-- EXIT OUTLOOK

This year's conference sponsors include: SRI International, ABD
Insurance & Financial Services, GE Healthcare Financial Services
Life Science Finance, O'Melveny & Myers LLP and Charter Life
Sciences.

SOURCE: IBF Conferences Inc.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/